文献速递消化系统肿瘤

早发性胰腺癌的临床与基因组特征分析

Clinical and genomic characterisation of early-onset pancreatic cancer.
PubMed 文献 · Eur J Cancer · 2023-09-09

该单中心回顾性研究纳入336例胰腺癌患者(早发组≤50岁139例,对照组≥70岁197例),比较两组临床与基因组特征。早发组吸烟比例更高、糖尿病患病率更低、体能状态更好、CA19.9及白蛋白水平更高;校正基线协变量后总生存无差异。早发组可靶向变异(ESCAT I-IIIA级)更常见,一线转移治疗中无进展生存及总生存更优。

要点

  • 早发组与对照组校正后总生存无差异,但一线转移治疗中早发组无进展生存(HR 0.61)和总生存(HR 0.65)更优
  • 早发组可靶向变异(ESCAT I-IIIA级)更常见:发现队列19% vs 14%,验证队列14% vs 8%
  • 早发组接受靶向治疗者总生存优于未接受者(HR 0.34)

核心结论

  • 早发性胰腺癌患者在转移阶段结局优于晚发性胰腺癌患者,且富集可靶向变异,为精准肿瘤学方法提供了机会。

研究设计与样本

  • 单中心回顾性比较分析,纳入符合全部入组标准的336例患者(早发性胰腺癌≤50岁139例,晚发性胰腺癌≥70岁197例),比较临床、胚系及基因组特征,关键分子发现与外部公开队列比较。

主要发现

  • 早发性胰腺癌与吸烟状态、较低糖尿病患病率、较好体能状态、较高CA19.9水平及较高白蛋白水平相关。
  • 校正基线协变量后,早发性与晚发性胰腺癌总生存无差异。
  • 年龄与KRASMUT发生率增加相关,在本队列和验证队列中均观察到。
  • 与晚发性胰腺癌相比,早发性胰腺癌在发现队列和验证队列中均富集ESCAT I-IIIA级可靶向变异(发现队列19% vs 14%,验证队列14% vs 8%)。
  • 一线转移治疗中,早发性胰腺癌无进展生存更长(HR 0.61,95%CI 0.43-0.87),总生存更长(HR 0.65,95%CI 0.45-0.95),但缓解率无差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The incidence of early-onset pancreatic cancer (EOPC) has risen dramatically in recent years. We aimed to characterise the clinical and genomic features of EOPC and evaluate their therapeutic implications. METHODS: We performed a comparative, single-centre, retrospective analysis of clinical, germline, and genomic features in EOPC (≤50 years) patients and compared them with a control group of average-onset pancreatic cancer patients (AOPC, ≥70 years). Key molecular findings were compared with an external, publicly available cohort. RESULTS: We reviewed 336 patients who met all inclusion criteria (EOPC N = 139, AOPC N = 197). EOPC was associated with smoking status, lower prevalence of diabetes, better performance status, higher CA19.9 levels, and higher albumin levels at diagnosis. After adjustment for baseline covariates, we observed no differences in overall survival (OS). Age was associated with an increase in the incidence of KRASMUT both in our cohort and the validation cohort. EOPC were enriched in potentially actionable alterations according to ESCAT tiers I-IIIA when compared with AOPC in discovery and validation cohorts (19% versus 14% and 14% versus 8%, respectively). In the first-line metastatic setting, EOPC had a longer progression-free survival (hazard ratio [HR] 0.61, 95% confidence interval (CI) 0.43-0.87) and OS (HR 0.65, 95% CI 0.45-0.95), although there were no differences in response rate. After adjusting for the number of treatment lines, EOPC patients who did receive targeted therapies exhibited longer OS compared with EOPC who did not (HR 0.34, 95% CI 0.12-0.93). CONCLUSIONS: EOPC patients have improved outcomes in the metastatic setting when compared to AOPC and are enriched for targetable alterations that open opportunities for precision oncology-based approaches.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Castet F, Fabregat-Franco C, Castillo G, et al. Clinical and genomic characterisation of early-onset pancreatic cancer. Eur J Cancer. 2023. PMID: 37793216. doi:10.1016/j.ejca.2023.113338

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。